Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) Research & Development (2016 - 2025)

CorMedix's Research & Development history spans 13 years, with the latest figure at $8.6 million for Q4 2025.

  • For Q4 2025, Research & Development rose 398.14% year-over-year to $8.6 million; the TTM value through Dec 2025 reached $19.3 million, up 224.65%, while the annual FY2025 figure was $19.3 million, 390.44% up from the prior year.
  • Research & Development for Q4 2025 was $8.6 million at CorMedix, up from $5.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $8.6 million in Q4 2025 and bottomed at $727119.0 in Q3 2024.
  • The 5-year median for Research & Development is $2.8 million (2022), against an average of $3.2 million.
  • The largest annual shift saw Research & Development plummeted 75.42% in 2024 before it soared 601.07% in 2025.
  • A 5-year view of Research & Development shows it stood at $3.2 million in 2021, then fell by 12.12% to $2.8 million in 2022, then decreased by 6.3% to $2.7 million in 2023, then plummeted by 35.19% to $1.7 million in 2024, then skyrocketed by 398.14% to $8.6 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Research & Development are $8.6 million (Q4 2025), $5.1 million (Q3 2025), and $2.4 million (Q2 2025).